Last updated: June 5, 2026
OSMITROL 5% IN WATER IN PLASTIC CONTAINER: Who supplies it and what’s the upstream sourcing map?
OSMITROL 5% in Water in plastic container is a hospital-use liquid osmotic agent (mannitol solution). The practical supplier universe is defined by (1) U.S.-market labeling/manufacturer of record and (2) upstream sourcing of finished-manufactured drug product or contract-manufactured sterile mannitol solution.
Who are the labeled manufacturers and distributors for OSMITROL 5% in water (plastic container) in the U.S.?
Featured-snippet answer: The supplier for this specific branded presentation is the labeled manufacturer/distributor shown on the U.S. container label and associated FDA drug registration and listing records for OSMITROL (mannitol) 5% in plastic container.
What “plastic container” implies for supply chain
- “Plastic container” for mannitol solutions in the U.S. is typically associated with prefilled IV plastic systems (brand- and site-dependent), which means supply is often split between:
- Finished drug product sites (sterile compounding/terminal processing, fill-finish)
- Container system suppliers (bag systems and ports)
- Packaging and distribution entities (labelers/distributors)
What counts as a “supplier” for procurement
- Pharmacy procurement usually treats the “supplier” as the company that ships the labeled product to wholesalers and hospitals.
- Contract-manufacturing and container supply are still relevant when identifying manufacturing/IP barriers or substitution feasibility, but they are not usually visible in routine purchasing.
How do suppliers break down: drug product manufacturer vs container/packaging supplier?
Featured-snippet answer: In mannitol IV products, the market typically separates sterile drug-product manufacturing from container systems, even when the final label brand is controlled by a different entity.
Common upstream roles in 5% mannitol IV solution
- Sterile drug-product manufacturer (fill-finish)
Produces sterile mannitol solution, performs sterilization/aseptic processing as applicable, then fills into the container system.
- Plastic container system supplier
Provides the IV bag components, ports, and sealing materials used for the “plastic container” presentation.
- Labeler/distributor
Controls the NDC listing, labeling, and sales channel into wholesalers and institutions.
Which upstream companies supply the raw material: mannitol used for 5% IV solutions?
Featured-snippet answer: Upstream mannitol supply is controlled by bulk chemical producers with GMP capabilities for pharmaceutical grade, but finished IV supply is dominated by sterile manufacturers and contract fill-finish partners.
Raw-material supplier archetypes
- Bulk pharmaceutical-grade mannitol producers (crystal mannitol GMP)
- Specialty excipient suppliers that also manufacture quality-controlled pharmaceutical bulks
- Sourcing through tolling and multi-supplier qualification for fixed formulations
What is the regulatory trace: who is the FDA-registered manufacturing establishment for OSMITROL 5%?
Featured-snippet answer: The manufacturing establishment responsible for the marketed sterile product is the FDA-registered site tied to the specific NDC for OSMITROL 5% in water in plastic container.
Why NDC specificity matters
- “OSMITROL 5% in water in plastic container” can map to more than one NDC, strength presentation, or container configuration.
- Each NDC can have different listed manufacturers and repackagers, changing the supplier list materially.
What generic substitution risks exist if OSMITROL is sourced from different suppliers?
Featured-snippet answer: Substitution risk is driven by container/route equivalency and sterility/packaging specifications, not only the API.
Key substitution friction points
- Container type and port system (compatibility with infusion sets)
- Volume per bag (e.g., 100 mL, 250 mL, 500 mL) which affects dosing and IV workflow
- Osmolality/tonicity targets consistent with the labeled 5% specification
- Stability and sterility assurance for the packaging configuration
How can procurement teams map alternatives when OSMITROL supply tightens?
Featured-snippet answer: Build an alternative list at the NDC/manufacturer level, not only by “mannitol 5% IV,” then validate infusion compatibility with the specific plastic container system.
Operational procurement mapping
- Identify current labeled manufacturer of record (for the exact NDC)
- Identify same-strength, same-container-type alternatives
- Confirm wholesaler inventory by NDC and labeler
- Validate product handling requirements and expiration dating for the specific pack
Key Takeaways
- “Supplier” for OSMITROL 5% in water in plastic container should be defined as the labeled manufacturer/distributor tied to the exact NDC for the plastic-container presentation.
- Upstream sourcing typically splits into sterile drug-product manufacturing (fill-finish) and plastic container system supply.
- Substitution and availability risk depends on NDC-level details: container configuration, volume per bag, and the specific manufacturing establishment.
FAQs
- Does OSMITROL 5% in plastic container have different suppliers by NDC?
- Are plastic-container IV bag systems interchangeable across different mannitol brands?
- What determines whether a mannitol IV product is considered substitutable in hospitals?
- How do FDA listings typically reflect the drug product manufacturer versus labeler?
- What are the main supply-chain choke points for sterile mannitol 5% IV solutions?
References
- FDA. Drugs@FDA. Accessed via Drugs@FDA database.
- FDA. NDC Directory and Drug Registration and Listing (DRLM) data. Accessed via FDA databases.
- FDA. Orange Book (if applicable for referenced product approvals). Accessed via FDA databases.
